Literature DB >> 2952710

Antibodies to the common leukocyte antigen (T200) inhibit an early phase in the activation of resting human B cells.

R S Mittler, R S Greenfield, B Z Schacter, N F Richard, M K Hoffmann.   

Abstract

T191, a monoclonal antibody reactive with the T200 common leukocyte antigen, profoundly inhibits an early event(s) associated with alpha-immunoglobulin M (alpha IgM)/T cell replacing factor (TRF) or alpha IgM/recombinant interleukin 1 and 2 (rIL 1 and rIL 2)-induced tonsillar B cell proliferation. Kinetic analysis of T191-mediated inhibition indicated that the antibody exerts its effect within 12 to 24 hr of the initiation of cultures and rapidly loses its activity thereafter. Small resting B cells are most sensitive to T191 inhibition, whereas B cells with increasing buoyant density (presumably reflecting stages of increased activation) become progressively T191 insensitive. Analysis of RNA synthesis subsequent to alpha IgM crosslinking of surface immunoglobulin demonstrated that T191 reduced [3H]uridine incorporation by up to 38% during the first 20 hr of culture. In contrast to the effects seen with alpha IgM stimulated B cells, T191 had no inhibitory effect upon phorbol myristate acetate-induced B cell proliferation. The inhibitory effect upon B cell proliferation observed with T191 is not unique among other alpha-T200 antibodies. Four of five previously described alpha-T200 monoclonal antibodies had similar inhibitory effects (82 to 57% maximum inhibition of [3H]thymidine incorporation). However, 13.3, an alpha-T200 monoclonal antibody previously shown to block natural killer (NK) cell-mediated killing was without effect. Likewise, those antibodies capable of inhibiting B cell proliferation failed to block NK-mediated cytolysis. Antibody binding experiments together with proliferation inhibition studies suggest that all of the monoclonal antibodies tested recognized distinct epitopes on the T200 antigen. Both observations are of significance because they demonstrate that the effects seen with anti-T200 antibodies represent an interference with highly specific functional regions on the T200 molecules.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2952710

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Anti-CD45 isoform antibodies enhance phagocytosis and gene expression of IL-8 and TNF-alpha in human neutrophils by differential suppression on protein tyrosine phosphorylation and p56lck tyrosine kinase.

Authors:  C- L Yu; H-S Yu; K-H Sun; S-C Hsieh; C-Y Tsai
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

2.  Tyrosine phosphatase CD45 is required for T-cell antigen receptor and CD2-mediated activation of a protein tyrosine kinase and interleukin 2 production.

Authors:  G A Koretzky; J Picus; T Schultz; A Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

Review 3.  Surface molecules involved in B lymphocyte function.

Authors:  P Möller; A Eichelmann; G Moldenhauer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

4.  Anti-leucocyte common (CD45) antibodies inhibit dendritic cell stimulation of CD4 and CD8 T-lymphocyte proliferation.

Authors:  T C Prickett; D N Hart
Journal:  Immunology       Date:  1990-02       Impact factor: 7.397

Review 5.  Surface proteins and glycoproteins of human leucocytes.

Authors:  V Horejsí; V Bazil
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

6.  CD45 expression by murine B cells and T cells: alteration of CD45 isoforms in subpopulations of activated B cells.

Authors:  K S Hathcock; H Hirano; R J Hodes
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

7.  Expression of CD45 alters phosphorylation of the lck-encoded tyrosine protein kinase in murine lymphoma T-cell lines.

Authors:  H L Ostergaard; D A Shackelford; T R Hurley; P Johnson; R Hyman; B M Sefton; I S Trowbridge
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

8.  Differential effects of CD45 CD45R and CD45R0 monoclonal antibodies in modulating human B cell activation.

Authors:  D L Deane; E Harvey; C M Steel
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

9.  Carbohydrate specificity of IgM autoantibodies to CD45 in systemic lupus erythematosus.

Authors:  P D Fernsten; J K Czyzyk; T Mimura; J B Winfield
Journal:  Mol Biol Rep       Date:  1994       Impact factor: 2.316

10.  Intimate association of Thy-1 and the T-cell antigen receptor with the CD45 tyrosine phosphatase.

Authors:  S Volarević; C M Burns; J J Sussman; J D Ashwell
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.